您现在的位置:澳门mgm美高梅网站 > 教师名录

导师代码:12194

导师姓名:蔡璐璐

性  别:

出生年月:1984年07月

特  称:四川省人社厅学术和技术带头人后备人

职  称:副研究员

学  位:博士

属  性:专职

电子邮件:cailulu@med.uestc.edu.cn

2018/9-至今,美国加州大学洛杉矶分校(UCLA), 生物工程系, 访问助理项目科学家,合作导师, 顾臻 教授; 2017/5-2018/8,美国北卡罗来纳大学教堂山分校/北卡罗来纳州立大学, 生物医学工程系, 博士后助理,合作导师, 顾臻 教授; 2016/5-2017/5,电子科技大学医学院(四川省人民医院), 药学部, 副研究员; 2014/6-2017/5,四川大学, 生物治疗国家重点实验室,在职博士后,导师:魏于全 院士; 2014/5-2015/5,日本京都药科大学, 药剂学分野,中国卫生部-日本医学协会第34期“笹川医学奖学金”进修生,导师:山本 昌 教授 2012/7-2016/4,四川省人民医院,药学部,助理研究员; 2007.09-2012.07 四川大学生物治疗国家重点实验室 硕博连读 药学博士
学术经历:
蔡璐璐,副研究员,博士,硕士研究生导师,四川省人社厅学术和技术带头人后备人, 主持国家自然科学青年基金及四川省杰出青年科学基金。中国医药生物技术协会纳米生物技术分会委员,四川省药学会药物流行病学专委会委员,中国抗癌协会纳米肿瘤学专业委员会专业会员,中国抗癌协会肿瘤药物临床研究专业委员会专业会员,中国抗癌协会肿瘤精准治疗专业委员会专业会员,中国抗癌协会肿瘤分子医学专业委员会专业会员,免疫学会肿瘤免疫学分会会员, 成都药学学会会员。 近十年来致力于肿瘤治疗领域新药新制剂的研究与开发。先后承担了国家自然科学青年基金,国家博士后基金面上项目,四川省杰出青年科学基金,四川省科技厅科技支撑项目,四川省卫生计生委应用基础项目,四川省中医药管理局青年项目等各级科研项目,曾参与863国家级科研项目、科技部“十一五”药物重大专项资助和四川省科技厅科技攻关重点项目等各级项目。主要研究成果发表在 Nano Research (IF=7.994), Nanoscale (IF=7.233),Drug Discovery Today (IF=6.369),J Biomed Nanotechnol (IF=5.068), J Mater Chem B (IF=4.776),Int J Nanomed (IF=4.370)及Int J Pharm (IF=3.862) 等SCI杂志上30余篇。论文被Nat Rev Microbiol, Pharmacol Rev, Nanotoxicology,J Control Release,Biomaterials,Cancer Treat Rev等国际期刊引用600余次,H因子13 (谷歌 Scholar数据)。同时受邀担任Nano Research, Nanoscale, Biomaterials, Int J Pharm, Int J Nanomed等国际杂志的审稿人。已申请纳米药物方向中国发明专利7项。
个人概况:
主要涉及肿瘤治疗领域新药新制剂的研究与开发。主持国家自然基金青年基金1项;中国博士后面上基金1项;四川省杰出青年科技基金1项;四川省科技厅科技支撑计划项目1项; 四川省卫生计生委应用基础项目1项;四川省中医药管理局青年项目一项;四川省人社厅留学择优资助项目1项;与企业合作横向项目1项。
科研项目:
近年来主要代表作: 1. Advances in glycosylation-mediated cancer-targeted drug delivery. Drug Discovery Today, 2018, 23(5), 1126-1138. 2. Tumor microenvironment-responsive hyaluronate-calcium carbonate hybrid nanoparticle enables effective chemotherapy for primary and advanced osteosarcomas. Nano Research, 2018, 11(9): 4806–4822. 3. Synthesis, mechanical investigation, and application of nitrogen and phosphorus co-doped carbon dots with a highly photoluminescent quantum yield. Nano Research, 2018, 11(7): 3691–3701. 4. Multidimensional theranostics for tumor fluorescence imaging, photoacoustic imaging and photothermal treatment based on manganese doped carbon dots. J Biomedical Nanotechnology, 2018, 14 (9), 1590-1600. 5. Gambogic acid-loaded polymeric micelles for improved therapeutic effect in breast cancer. J Biomedical Nanotechnology, 2018,14 (10), 1695-1704. 6. Synthesis of highly fluorescent yellow‐green N‐doped carbon nanorings for pH variation detection and bioimaging. Particle & Particle Systems Characterization, 2018:1800276. 7. The application of natural products in cancer therapy by targeting apoptosis pathways. Current drug metabolism, 2018,19 (9), 739-749. 8. Efficient cocktail chemotherapy by co-delivery of hydrogen sul?de-releasing aspirin prodrug and paclitaxel via single nanoparticles. RSC Advances, 2017, 7, 13458–13466. 9. Highly fluorescent Zn-doped carbon dots as Fenton reaction-based bio-sensors: an integrative experimental–theoretical consideration. Nanoscale, 2016, 8(41): 17919-17927. 10. Heteroatom-doped carbon dots: synthesis, characterization, properties, photoluminescence mechanism and biological applications. Journal of Materials Chemistry B, 2016, 4(45): 7204-7219. 11. Comparative study of (Asp) 7-CHOL modified liposome prepared using pre-insertion and post-insertion methods for bone targeting in vivo. Journal of Drug Targeting, 2016, 25:149–155. 12. An integrated in silico method to discover novel rock1 inhibitors: multi-complex-based pharmacophore, molecular dynamics simulation and hybrid protocol virtual screening. Combinatorial chemistry & high throughput screening, 2016, 19: 36-50. 13. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors. Journal of Biomolecular Structure and Dynamics, 2016: 34(2), 341-351. 14. Novel naproxen-peptide-conjugated amphiphilic dendrimer self-assembly micelles for targeting drug delivery to osteosarcoma cells. RSC Advances. 2016, 6: 60327-60335. 15. Barbigerone-in-hydroxypropyl-β-cyclodextrin-liposomal nanoparticle: preparation, characterization and anti-cancer activities. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2015, 82(3-4): 505-514. 16. Synthesis and in vitro evaluation of 4-substituted furano [3, 2-c] tetrahydroquinolines as potential anti-cancer agents. Journal of enzyme inhibition and medicinal chemistry, 2015: 1-6. 17. Improving aqueous solubility and antitumor effects by nano-sized gambogic acid-mPEG2000 micelles. Int J Nanomedicine. 2014, 9: 1-13. 18. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR over-expressing tumor in vivo. Int J Nanomedicine. 2012, 7: 4499-510. 19. Preparation of the thienopyridine derivatives loaded liposomes and study on the effect of compound-lipid interaction on release behavior. Drug Deliv. 2012, 19(5): 247–254. 20. A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation. Int J Nanomedicine. 2012:7 2601–2611. 21. Liposomal curcumin inhibits Lewis lung cancer growth primarily through inhibition of angiogenesis. Oncology Letters. 2012, 4: 107-112. 22. A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells. Int J Pharmaceut. 2011, 408: 173–182. 23. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. Int J Pharmaceut. 2011, 410: 169–174. 24. Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: Improved pharmacokinetics and biodistribution in tumor-bearing mice. J Pharm Sci. 2011, 100: 1196–1205. 25. Preparation, Characterization, Pharmacokinetics and Bioactivity of Honokiol-in-Hydroxypropyl-β-Cyc-lodextrin-in-Liposome. J Pharm Sci. 2011, 100: 3357–3364. 26. Synthesis, structural and in vitro studies of well-dispersed monomethoxypoly (ethylene glycol)–honokiol conjugate micelles. Biomed mater. 2010, 5: 065006. 27. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. Journal of Controlled Release, 2010, 145(1): 17-25. 28. Schistosoma japonicum: efficient and rapid purification of the tetraspanin extracellular loop 2, a potential protective antigen against schistosomiasis in mammalian. Exp Parasitol. 2010, 126: 456-461.
发表文章:

硕士招生专业

105500 药物研究与转化

02方向: 药物研究与转化

博士招生专业

XML 地图 | Sitemap 地图